Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma

Pembrolizumab is a humanised therapeutic antibody against the PD-1 receptor. It has been used in various advanced cancer immunotherapies. Here, we report an extremely rare case of a 32-year-old man who developed Stevens-Johnson syndrome (SJS) with porokeratosis simultaneously during pembrolizumab treatment for primary hepatocellular carcinoma (T3N1M1).

Automated summary

This study reports an extremely rare case of a 32-year-old man who developed Stevens-Johnson syndrome and porokeratosis simultaneously during pembrolizumab treatment for primary hepatocellular carcinoma.